NASDAQ · Biotechnology

Veraxa Biotech Holding AG (VRXA) Stock

$1.82 +1.11% NASDAQ: VRXA Healthcare

Veraxa Biotech Holding AG is a clinical-stage biopharmaceutical company, formed via a merger with Voyager Acquisition Corp., focusing on developing next-generation cancer therapies such as antibody-drug conjugates (ADCs) and bispecific T-cell engagers. [64, 65]

Valuation

MetricValue
Price$1.82
Market Cap$257.36M
P/E Ratio—
P/B Ratio—
P/S Ratio—
EPS (TTM)—
52-Week High$27.36
52-Week Low$1.70
Dividend Yield—

Financials & Margins

MetricValue
ROE—
ROA—
ROCE—
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity—
Current Ratio—

Latest News

VERAXA Biotech (VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform NewMediaWire · Jul 20, 2026 VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan GlobeNewswire · Jul 20, 2026 Why VERAXA Biotech (VRXA) Could Benefit More Than Others From AI's Growing Impact on Drug R&D NewMediaWire · Jul 15, 2026 VERAXA Biotech (VRXA) Partners With Ardigen to Advance AI-Driven Cancer Drug Development NewMediaWire · Jul 13, 2026 VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline GlobeNewswire · Jul 13, 2026

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield—
Quick Ratio—
Interest Coverage—
Return 1Y-82.21%
Return 3Y—
Return 5Y—

Ownership

Insiders Held71.15%
Institutions Held11.27%
Institutions Float Held39.05%
Institutional HolderSharesReport Date
Fidelity Commonwealth Trust-Fidelity Nasdaq Composite Index ETF33,7562026-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Veraxa Biotech Holding AG

Veraxa Biotech Holding AG is a clinical-stage biopharmaceutical company, formed via a merger with Voyager Acquisition Corp., focusing on developing next-generation cancer therapies such as antibody-drug conjugates (ADCs) and bispecific T-cell engagers. [64, 65]

Veraxa Biotech Holding AG is headquartered in DE.

Veraxa Biotech Holding AG (VRXA) stock trades at $1.82 with a market capitalization of $257.36M. Over the past 52 weeks the stock has ranged between $1.70 and $27.36, and currently trades 93.3% below its 52-week high.

On profitability, Veraxa Biotech Holding AG generates an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.veraxa.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides